Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells

BRAF inhibitor (BRAFi) therapy for melanoma patients harboring the V600E mutation is initially highly effective, but almost all patients relapse within a few months. Understanding the molecular mechanisms underpinning BRAFi-based therapy is therefore an important issue. Here we identified a previous...

Descripción completa

Detalles Bibliográficos
Autores principales: Faião-Flores, F, Alves-Fernandes, D K, Pennacchi, P C, Sandri, S, Vicente, A L S A, Scapulatempo-Neto, C, Vazquez, V L, Reis, R M, Chauhan, J, Goding, C R, Smalley, K S, Maria-Engler, S S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378933/
https://www.ncbi.nlm.nih.gov/pubmed/27748762
http://dx.doi.org/10.1038/onc.2016.348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378933/
https://www.ncbi.nlm.nih.gov/pubmed/27748762
http://dx.doi.org/10.1038/onc.2016.348

Ejemplares similares